[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467472":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":19,"centralContacts":30,"locations":37,"responsibleParty":54,"collaborators":19,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":19,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":40,"whyStopped":19,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"NAC plus RCT","EXPERIMENTAL","two circles of NAC with albumin-bound paclitaxel and carboplatin followed by standard chemoradiation with weekly cisplatin plus pelvic radiation",[13,14],"Drug: Albumin-Bound Paclitaxel","Drug: Carboplatin",{"label":16,"type":17,"description":18,"interventionNames":19},"RCT","NO_INTERVENTION","standard chemoradiation with weekly cispatin plus pelvic radiation",null,[21,26],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":19},"DRUG","Albumin-Bound Paclitaxel","260mg\u002Fm2 q3w \\*2 circles",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":19},"Carboplatin","AUC 5-6 q3w \\* 2 circles",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Junyun Li, M.D.","CONTACT","020-87343817","86","LIJUNY@sysucc.org.cn",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdone","510000","China","CN",{"type":47,"coordinates":48},"Point",[49,50],113.25,23.11667,{"lat":50,"lon":49},[53],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Li Junyun","Principal Investigator","100467472","phase-3-neoadjuvant-chemotherapy-followed-by-chemoradiation-versus-chemoradiation-for-stage-iiic-cervical-cancer-patients-a-randomized-phase-iii-trial-100467472",false,"NCT05367206","Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial","Department of Radiation, Sun Yat-sen University","N6C","Inclusion Criteria:\n\n1. pathologically comfirmed : squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix；\n2. FIGO (2018 International Federation of Gynecology and Obstetrics) stage IIIC with carcinoma \\>4 cm in greatest dimension and\u002For lymph node \\>2 cm in short axis at initial diagnosis.\n3. age 18 to 70 years；\n4. Eastern Cooperative Oncology Group performance status 0 to 2；\n5. adequate organ function.\n\nExclusion Criteria:\n\n1\\. not at initial diagnosis; 2. with other kind of tumor.\n\n\\-","FEMALE","18 Years","70 Years",{"count":70,"type":71},280,"ESTIMATED","INTERVENTIONAL",[74],"PHASE3","Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma \\>4 cm in greatest dimension and\u002For lymph node \\>2cm in short axis.",[77,78,79],"Cervical Cancer","Neoadjuvant Chemotherapy","Bulky Neoplasm",[81,82,83],"cervical cancer","neoadjuvant chemotherapy","bulky neoplasm","2022-05-09",{"date":86,"type":87},"2022-05-10","ACTUAL",{"date":89,"type":87},"2022-03-14",{"date":91,"type":71},"2027-03-31",{"name":5,"class":6},1]